Go Pro
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.80
-6.3%		$1.58
$0.77
▼
$524.00
$810K0.811.15 million shs191,439 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-5.1%		$0.01
$0.00
▼
$0.02
$981K-1.3215,814 shs100,678 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
-16.9%		$0.04
$0.01
▼
$6.66
$223K0.06216,668 shs105,016 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00%-16.83%-53.53%-73.81%-99.80%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-3.90%0.00%-12.94%-47.52%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%-27.22%-59.00%-83.60%-99.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.80
-6.3%		$1.58
$0.77
▼
$524.00
$810K0.811.15 million shs191,439 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-5.1%		$0.01
$0.00
▼
$0.02
$981K-1.3215,814 shs100,678 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.01
-16.9%		$0.04
$0.01
▼
$6.66
$223K0.06216,668 shs105,016 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00%-16.83%-53.53%-73.81%-99.80%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-3.90%0.00%-12.94%-47.52%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%-27.22%-59.00%-83.60%-99.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$12.71 per shareN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.09N/AN/A($2.64) per share0.00
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.04N/AN/A$2.46 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$3.86M-$40.55N/AN/AN/AN/A-88.53%-61.62%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.13N/AN/AN/A-46.42%-91.97%-61.93%N/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)

Latest PRPH, NMTR, EVFM, and CMND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/10/2026Q3 2026
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.57N/A-$0.57N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.01
4.31
4.31
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14

Institutional Ownership

CompanyInstitutional Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.01%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
41.02 millionN/ANot Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120132.53 million113.12 millionNot Optionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13018.12 million5.44 millionNo Data

Recent News About These Companies

ProPhase Labs Delays Quarterly SEC Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Inc.
July 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/prph/financials/cash-flow
ProPhase Labs Announces Immediate Resignation of Board Member
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRPH/pressreleases/36984840/prophase-labs-announces-immediate-resignation-of-board-member/
ProPhase Labs Delays Quarterly Financial Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-financial-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274530/0/en/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform.html
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
March 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-provides-business-highlighting-120000129.html
ProPhase Labs Explores Strategic Options for BE-Smart Test
February 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-explores-strategic-options-for-be-smart-test?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs, Inc.: ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart and Advances Crown Medical Collections Initiative
February 3, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67599969-prophase-labs-inc-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart-and-advances-crown-medical-collections-initiative-399.htm
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
February 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-initiates-potential-sale-120000291.html
ProPhase Labs initiates potential sale or strategic partnership of BE-Smart
February 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4546120-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
February 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/join-prophase-labs-exclusive-live-investor-webinar-and-q-a-session-on-february-3rd-1035773219
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-approximately-50-matters-in-advanced-settlement-posture-1035745250
ProPhase Labs Secures Flexible $10 Million Equity Facility
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-secures-flexible-10-million-equity-facility?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Uplists from Pink Sheets to OTC Market
January 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-uplists-from-pink-sheets-to-otc-market-1035736260
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212517/0/en/prophase-labs-provides-update-on-convertible-debt-conversions-capital-structure-and-underlying-asset-value.html
ProPhase Labs faces NASDAQ delisting, plans appeal, OTC move
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/prophase-labs-faces-nasdaq-delisting-plans-appeal-otc-move/ar-AA1TtNWj
ProPhase Labs signs non-binding LOI for proposed reverse merger with ABL
December 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-abl/ar-AA1SGkg8
ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger
December 19, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abl-diagnostics-informs-market-non-070000608.html
ProPhase Labs stock soars after announcing reverse merger with ABL
December 19, 2025  |  au.investing.comhttps://au.investing.com/news/stock-market-news/prophase-labs-stock-soars-after-announcing-reverse-merger-with-abl-93CH-4179598
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
December 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/19/3208405/0/en/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-advanced-biological-laboratories.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$0.80 -0.05 (-6.29%)
Closing price 09/18/2026 03:58 PM Eastern
Extended Trading
$0.79 -0.01 (-1.24%)
As of 09/18/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0074 0.00 (-5.13%)
As of 09/18/2026 03:50 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.01 0.00 (-16.89%)
As of 09/18/2026 03:51 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas